Teva’s Francis: I Looked At All The Sexy Stuff And Overlooked Olanzapine
Key Data Read Out For Long-Acting Subcutaneous Olanzapine Set For 2025
After launching the Uzedy long-acting formulation of risperidone in partnership with MedinCell earlier this year, Teva has stressed the “really exciting” product profile of another long-acting antipsychotic from the partnership, olanzapine, while discussing how it will avoid the safety pitfalls of legacy products in the space.